会上还公布了BTK抑制剂在自身免疫性疾病中最广泛的综合安全性数据集。该分析利用了来自3项2期临床试验1083例系统性红斑狼疮(SLE)、类风湿性关节炎(RA)RMS患者的汇总数据,包括不同剂量(25mg或75mg每日一次,或50mg或75mg每日2次)。分析显示,evobrutinib总体耐受性良好,与安慰剂相比不良事件发生率在适应症和跨试验...
In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by reduction of disease severity and histological damage. In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody production and plasma cell numbers, and normalized B and...
默克公司旨在通过解决医疗需求未得到满足的领域来改善患者的生活。除了默克对多发性硬化症的承诺,该公司还拥有一条专注于发现新疗法的管道,这些新疗法在其他神经炎症和免疫介导的疾病中具有潜力,包括系统性红斑狼疮(SLE)、全身性重症肌无力(gMG)和视神经脊髓炎谱系障碍(NMOSD)。 <END> 要解锁更多企业药品研发信息吗?...
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck...
Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD...
(BTKi), targets B cells, macrophages and microglia involved in autoimmunity.Design/Methods: Data from three phase II, randomized, double-blind, placebo-controlled trials of evobrutinib were analyzed (MS: n=213, 48 weeks, NCT02975349; RA: n=390, 12 weeks, NCT03233230; SLE: n=480, 52 ...
Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD...
We await data from yet other programs studying BTKi in SLE. e. CD40 CD40 is a receptor on B cells that mediates interactions with T cells [57]. It is a part of the tumor necrosis factor receptor family and activates B cells and a multitude of pathways that enhance B cell survival, ...
The treatment-related events/100 pt-years for Evobrutinib versus placebo were similar by indication: MS: 119.7 versus 148.3; RA: 331.8 versus 306.8; and SLE: 342.9 versus 302.1. The proportion of SAEs with Evobrutinib versus placebo was 11.8% versus 11.8% and 0.8% versus 0.7%, respectively...
该分析利用了来自3项2期临床试验1083例系统性红斑狼疮(SLE)、类风湿性关节炎(RA)RMS患者的汇总数据,包括不同剂量(25mg或75mg每日一次,或50mg或75mg每日2次)。分析显示,evobrutinib总体耐受性良好,与安慰剂相比不良事件发生率在适应症和跨试验中相似。报告的最常见不良事件为尿路感染(9.5% vs 8.5%[安慰剂])...